Viewing Study NCT07421167

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:18 PM
Ignite Modification Date: 2026-05-03 @ 12:44 PM
Study NCT ID: NCT07421167
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-02-19
First Post: 2026-02-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Immune Thrombocytopenia (ITP) View
None Primary Evans Syndrome (ES) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immune thrombocytopenia (ITP) View
None Evans syndrome (ES) View
None Ianalumab View
None VAY736 View
None B-cell depletion View
None B-cell Activating Factor Receptor (BAFF-R) View